Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Reperfusion therapy for ST-elevation myocardial infarction complicated by cardiogenic shock: the European Society of Cardiology EurObservational programme acute cardiovascular care-European association of PCI ST-elevation myocardial infarction registry

U. Zeymer, P. Ludman, N. Danchin, P. Kala, C. Laroche, CP. Gale, AP. Maggioni, S. Siabani, M. Sadeghi, A. Wafa, S. Bartus, F. Weidinger

. 2022 ; 11 (6) : 481-490. [pub] 2022Jun22

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017960

Grantová podpora
Abbott Vascular Int
Amgen Cardiovascular
AstraZeneca
Bayer AG
Boehringer Ingelheim
Boston Scientific
The Bristol Myers Squibb and Pfizer Alliance
Daiichi Sankyo Europe GmbH
The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company
Edwards
Gedeon Richter Plc
Menarini Int. Op
MSD-Merck & Co
Novartis Pharma AG
ResMed
Sanofi
SERVIER
Vifor
Abbott Vascular
Gedeon Richter
Novartis Pharma

AIMS: To determine the current state of the use of reperfusion and adjunctive therapies and in-hospital outcomes in European Society of Cardiology (ESC) member and affiliated countries for patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS). METHODS AND RESULTS: ESC EurObservational Research Programme prospective international cohort study of admissions with STEMI within 24 h of symptom onset (196 centres; 26 ESC member and 3 affiliated countries). Of 11 462 patients enrolled, 448 (3.9%) had CS. Patients with compared to patients without CS, less frequently received primary percutaneous coronary intervention (PCI) (65.5% vs. 72.2%) and fibrinolysis (15.9% vs. 19.0), and more often had no reperfusion therapy (19.0% vs. 8.5%). Mechanical support devices (intraaortic ballon pump 11.2%, extracoporeal membrane oxygenation 0.7%, other 1.1%) were used infrequently in CS. Bleeding definition academic research consortium 2-5 bleeding complications (10.1% vs. 3.0%, P < 0.01) and stroke (4.2% vs. 0.9%, P < 0.01) occurred more frequently in patients with CS. In-hospital mortality was 10-fold higher (35.5% vs. 3.1%) in patients with CS. Mortality in patients with CS in the groups with PCI, fibrinolysis, and no reperfusion therapy were 27.4%, 36.6%, and 62.4%, respectively. CONCLUSION: In this multi-national registry, patients with STEMI complicated by CS less frequently receive reperfusion therapy than patients with STEMI without CS. Early mortality in patients with CS not treated with primary PCI is very high. Therefore, strategies to improve clinical outcome in STEMI with CS are needed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017960
003      
CZ-PrNML
005      
20220804134502.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ehjacc/zuac049 $2 doi
035    __
$a (PubMed)35593654
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Zeymer, Uwe $u Klinikum der Stadt Ludwigshafen and Institut für Herzinfarktforschung, Ludwigshafen am Rhein, Germany $1 https://orcid.org/000000017077283X
245    10
$a Reperfusion therapy for ST-elevation myocardial infarction complicated by cardiogenic shock: the European Society of Cardiology EurObservational programme acute cardiovascular care-European association of PCI ST-elevation myocardial infarction registry / $c U. Zeymer, P. Ludman, N. Danchin, P. Kala, C. Laroche, CP. Gale, AP. Maggioni, S. Siabani, M. Sadeghi, A. Wafa, S. Bartus, F. Weidinger
520    9_
$a AIMS: To determine the current state of the use of reperfusion and adjunctive therapies and in-hospital outcomes in European Society of Cardiology (ESC) member and affiliated countries for patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS). METHODS AND RESULTS: ESC EurObservational Research Programme prospective international cohort study of admissions with STEMI within 24 h of symptom onset (196 centres; 26 ESC member and 3 affiliated countries). Of 11 462 patients enrolled, 448 (3.9%) had CS. Patients with compared to patients without CS, less frequently received primary percutaneous coronary intervention (PCI) (65.5% vs. 72.2%) and fibrinolysis (15.9% vs. 19.0), and more often had no reperfusion therapy (19.0% vs. 8.5%). Mechanical support devices (intraaortic ballon pump 11.2%, extracoporeal membrane oxygenation 0.7%, other 1.1%) were used infrequently in CS. Bleeding definition academic research consortium 2-5 bleeding complications (10.1% vs. 3.0%, P < 0.01) and stroke (4.2% vs. 0.9%, P < 0.01) occurred more frequently in patients with CS. In-hospital mortality was 10-fold higher (35.5% vs. 3.1%) in patients with CS. Mortality in patients with CS in the groups with PCI, fibrinolysis, and no reperfusion therapy were 27.4%, 36.6%, and 62.4%, respectively. CONCLUSION: In this multi-national registry, patients with STEMI complicated by CS less frequently receive reperfusion therapy than patients with STEMI without CS. Early mortality in patients with CS not treated with primary PCI is very high. Therefore, strategies to improve clinical outcome in STEMI with CS are needed.
650    12
$a kardiologie $7 D002309
650    _2
$a kohortové studie $7 D015331
650    _2
$a lidé $7 D006801
650    12
$a koronární angioplastika $x metody $7 D062645
650    _2
$a prospektivní studie $7 D011446
650    _2
$a registrace $7 D012042
650    _2
$a reperfuze $7 D015424
650    12
$a infarkt myokardu s elevacemi ST úseků $x komplikace $x diagnóza $x terapie $7 D000072657
650    _2
$a kardiogenní šok $x etiologie $x terapie $7 D012770
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ludman, Peter $u Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
700    1_
$a Danchin, Nicolas $u Hôpital Européen G. Pompidou, Service de Cardiologie, Paris, France
700    1_
$a Kala, Petr $u Internal Cardiology Department, Faculty of Medicine of Masaryk University, University Hospital Brno, Brno, Czech Republic
700    1_
$a Laroche, Cécile $u EURObservational Research Program, European Society of Cardiology, Sophia-Antipolis, France
700    1_
$a Gale, Chris P $u Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
700    1_
$a Maggioni, Aldo P $u EURObservational Research Program, European Society of Cardiology, Sophia-Antipolis, France $u Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy
700    1_
$a Siabani, Soraya $u Kermanshah University of Medical Sciences, Kermanshah, Iran
700    1_
$a Sadeghi, Masoumeh $u Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
700    1_
$a Wafa, Ahmed $u Mansoura Faculty of Medicine, Cardiology department, Mansoura, Egypt
700    1_
$a Bartus, Stanislaw $u Department of Cardiology, Jagiellonian University, Krakow, Poland
700    1_
$a Weidinger, Franz $u Hospital Rudolfstiftung, Vienna, Austria
773    0_
$w MED00186154 $t European heart journal. Acute cardiovascular care $x 2048-8734 $g Roč. 11, č. 6 (2022), s. 481-490
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35593654 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134456 $b ABA008
999    __
$a ok $b bmc $g 1821853 $s 1169203
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 11 $c 6 $d 481-490 $e 2022Jun22 $i 2048-8734 $m European heart journal. Acute cardiovascular care $n Eur Heart J Acute Cardiovasc Care $x MED00186154
GRA    __
$p Abbott Vascular Int
GRA    __
$p Amgen Cardiovascular
GRA    __
$p AstraZeneca
GRA    __
$p Bayer AG
GRA    __
$p Boehringer Ingelheim
GRA    __
$p Boston Scientific
GRA    __
$p The Bristol Myers Squibb and Pfizer Alliance
GRA    __
$p Daiichi Sankyo Europe GmbH
GRA    __
$p The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company
GRA    __
$p Edwards
GRA    __
$p Gedeon Richter Plc
GRA    __
$p Menarini Int. Op
GRA    __
$p MSD-Merck & Co
GRA    __
$p Novartis Pharma AG
GRA    __
$p ResMed
GRA    __
$p Sanofi
GRA    __
$p SERVIER
GRA    __
$p Vifor
GRA    __
$p Abbott Vascular
GRA    __
$p Gedeon Richter
GRA    __
$p Novartis Pharma
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace